EVALUATION OF SERUM LEVELS OF NETRIN-1 AS A POTENTIAL BIOMARKER FOR EARLY PREDICTION OF PREDIABETES

Öz

Objectives: Prediabetes is a candidate status for Type 2 diabetes, typically identified glycemic values range above normal but below diabetes thresholds. Early and accurate diagnosis of this period would be helpful to prevent the diabetes and its consequences. Netrin-1 is a potential metabolic biomarker that has been associated with diabetes. Previous studies are scarce and have yielded contrasting results on serum netrin-1 levels in diabetes. The aim of this study was to investigate the correlation between serum netrin-1 levels and prediabetes. Methods: Sixty nine participants with prediabetes and 35 healthy controls were included in this study. Serum netrin-1 levels were determined using the Enzyme Linked Immunosorbent Assay (ELISA) method. Correlation analysis were done to assess the relationship between serum netrin-1 levels and biochemical parameters. Results: Serum netrin-1 levels were significantly decreased in the prediabetes group compared to the healthy control group (P<0.0001). A significant negative correlation was observed between serum netrin-1 levels and age, hemoglobin A1c (HbA1c), sedimantation, fasting blood glucose (FBG) and C-reactive protein (CRP) (r = -0.2738, 0.2886, r = -0.3180; P<0.01, r = -0.3439 and r = -0.3987; P<0.01, respectively. Conclusion: Serum netrin-1 significantly negative-correlated with prediabetes and also with FBG and HbA1c. These results suggested that netrin-1 could be used as a biomarker for the early detection or screening of prediabetes.

Anahtar Kelimeler

• Netrin-1
• Prediabetes
• Biomarker

Kaynakça

1. 1. Priya G. Management of prediabetes. J Pak Med Assoc. 2018;68(4):669-671.
2. 2. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379(9833):2279-90.
3. 3. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33.
4. 4. Zand A, Ibrahim K, Patham B. Prediabetes: Why Should We Care? Methodist Debakey Cardiovasc J. 2018;14(4):289-297.
5. 5. Cirulli V, Yebra M. Netrins: beyond the brain. Nat Rev Mol Cell Biol. 2007; 8(4):296-306.
6. 6. Rajasekharan S, Kennedy TE. The netrin protein family. Genome Biol. 2009;10(9):239.
7. 7. Hedgecock EM, Culotti JG, Hall DH. The unc-5, unc-6, and unc-40 genes guide circumferential migrations of pioneer axons and mesodermal cells on the epidermis in C. elegans. Neuron. 1990; 4(1):61-85.
8. 8. Ishii N, Wadsworth WG, Stern BD, et al. UNC-6, a laminin-related protein, guides cell and pioneer axon migrations in C. elegans. Neuron. 1992;9(5):873-81.

9. 9. Serafini T, Colamarino SA, Leonardo ED, et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell. 1996; 87(6):1001-14.
10. 10. Mehlen P, Furne C. Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cell Mol Life Sci. 2005; 62(22):2599-616.
11. 11. Kefeli U, Ucuncu Kefeli A, Cabuk D, et al. Netrin-1 in cancer: Potential biomarker and therapeutic target? Tumour Biol. 2017;39(4):1010428317698388.
12. 12. Ramesh G, Berg A, Jayakumar C. Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers. 2011;16(2):172-80.
13. 13. Layne K, Ferro A, Passacquale G. Netrin-1 as a novel therapeutic target in cardiovascular disease: to activate or inhibit? Cardiovasc Res. 2015;107(4):410-9.
14. 14. Ramesh G, Kwon O, Ahn K. Netrin-1: a novel universal biomarker of human kidney injury. Transplant Proc. 2010;42(5):1519-22.
15. 15. Mehlen P, Guenebeaud C. Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol. 2010;22(1):46-54.
16. 16. Yim J, Kim G, Lee BW, et al. Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes. Front Endocrinol (Lausanne). 2018; 23(9):691.
17. 17. Liu C, Ke X, Wang Y, et al. The level of netrin-1 is decreased in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr Disord. 2016;16(1):33.
18. 18. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22(9):1462-70.
19. 19. Moore KJ, Fisher EA. Macrophages, atherosclerosis and the potential of netrin-1 as a novel target for future therapeutic intervention.Future Cardiol. 2012;8(3):349-52.
20. 20. Park KW, Crouse D, Lee M, et al. The axonal attractant Netrin-1 is an angiogenic factor. Proc Natl Acad Sci USA. 2004;101(46):16210-5.
21. 21. Ly NP, Komatsuzaki K, Fraser IP, et al. Netrin-1 inhibits leukocyte migration in vitro and in vivo. Proc Natl Acad Sci USA. 2005;102(41):14729-34.
22. 22. Mao X, Xing H, Mao A, et al. Netrin-1 attenuates cardiac ischemia reperfusion injury and generates alternatively activated macrophages. Inflammation. 2014; 37(2):573-80.
23. 23. Ranganathan PV, Jayakumar C, Ramesh G. Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. Am J Physiol Renal Physiol. 2013;304(7):F948-57.
24. 24. Yimer EM, Zewdie KA, Hishe HZ. Netrin as a Novel Biomarker and Its Therapeutic Implications in Diabetes Mellitus and Diabetes-Associated Complications. J Diabetes Res. 2018; 2018:8250521.
25. 25. Nedeva I, Gateva A, Assyov Y, et al. Relationship between circulating netrin-1 levels, obesity, prediabetes and newly diagnosed type 2 diabetes. Arch Physiol Biochem. 2020; 1-6. https://doi.org/10.1080/13813455.2020.1780453
26. 26. Ay E, Marakoglu K, Kizmaz M, et al. Evaluation of Netrin-1 Levels and Albuminuria in Patients With Diabetes. J Clin Lab Anal. 2016;30:972–7.
27. 27. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315-6.